Eduardo Martinez

Eduardo Martinez has a diverse work experience in the pharmaceutical and biotechnology industries. Eduardo started their career at Bristol-Myers Squibb as an Assistant Research Investigator, where they contributed to the development of drug candidates and optimized chemical processes. Eduardo then joined Ironwood Pharmaceuticals as a Principal Investigator, managing a team and developing small molecule inhibitors for various medical conditions.

Martinez also worked as a Visiting Researcher at The Rockefeller University and Janelia Research Campus, focusing on small molecule regulators of epigenetic signatures and conducting research in the field of neuroscience.

Eduardo co-founded Euclises Pharmaceuticals, Inc. and served as the Director of Drug Discovery, contributing to the company's mission of developing novel therapeutics. Eduardo later became the VP of Chemistry at Rgenix, Inc., where they worked on innovative projects related to gene expression.

Martinez's expertise also includes consulting for chemistry-driven start-ups through EJMMC Consulting, LLC, and serving as the Managing Member and Director of Operations at SARmont, LLC.

Eduardo'smost recent role was as the VP of Chemistry at Sea Pharmaceuticals, leading the development of synthetic small molecules for the treatment of CNS disorders. Throughout their career, Martinez has been involved in various aspects of drug discovery and development, including chemical design, management of CROs, patent writing, and strategy.

Eduardo Martinez pursued their education starting from 1989 to 1993 at UC Irvine, where they obtained a Bachelor of Science degree in Organic Chemistry. Following this, they continued their academic journey from 1996 to 2001 at the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences. There, they pursued a Doctor of Philosophy degree in Organic Chemistry.